KRTL Holding Group, Inc. (OTC: KRTL), a holding company with two subsidiaries, is pleased to announce its wholly owned subsidiary KRTL Biotech, Inc., are pleased to announce several significant developments that will shape the future of the organization.
First and foremost, the company would like to express its deep appreciation to Daniel Ball, who has served as CEO of KRTL Biotech, Inc. Under his strategic guidance, KRTL Biotech, Inc. has achieved remarkable milestones, including the negotiation of a partnership with a cybersecurity firm, Seven Cipher, a premier veteran-owned company offering AI-powered detection solutions that safeguard cloud, endpoint, and code-level infrastructure. Seven Cipher's extensive background collaborating with Fortune 500 companies, the Department of Defense, and the intelligence community has provided KRTL with customized security and compliance solutions that are at the forward edge of AI-assisted attack mitigation and full spectrum cybersecurity protection. This partnership allows KRTL to offer the Seven Cipher full suite of services as part of a KRTL branded comprehensive technology strategy in the Medtech, alternative medicine, medical device, and other technology sectors.
Additionally, Daniel Ball successfully negotiated an exclusive white-label partnership with Medflow, an AI-powered telemedicine solution that integrates advanced facial recognition biometrics within a next-generation zero-trust security architecture. This arrangement enables KRTL to offer accurate verification of patient identities, live heartrate, breathing, and other vital capture without hardware assistance. It further reinforces KRTL’s commitment to leveraging technology to advance quality and efficiency of care in ensure technical and alternative wellness sectors and ensures access to products that can support stakeholder priorities.
Mr. Ball’s work in these areas alongside his efforts in establishing exclusive mobile extraction capabilities, international opportunity zone access, and other business development footholds have positioned KRTL with “go-to-market” readiness on multiple fronts. As part of the company's ongoing growth and development, Daniel Ball will be transitioning from his role as CEO to join KRTL Biotech, Inc.'s advisory board. In this capacity, he will lend his expertise to support the company's ongoing and overarching technology and infrastructure development, ensuring a seamless transition and continuity of vision.
KRTL Biotech, Inc. is delighted to welcome Dr. Stefan Kasian as the incoming CEO. Dr. Kasian brings a wealth of knowledge and experience to lead KRTL Biotech, Inc. into the next phase of its evolution geared toward customer acquisition and product growth. His strategic vision and commitment to innovation make him the ideal candidate to drive the company's continued success.
The meticulous planning that led to these changes reflects KRTL Biotech, Inc.'s dedication to providing the highest level of technology and biotechnical solutions. With these strategic partnerships and the new leadership in place, KRTL Biotech, Inc. is poised to make significant advancements in the industry.
"We are grateful to Daniel Ball for his exceptional leadership and numerous accomplishments during his tenure as CEO," said Cesar Herrera, CEO of KRTL Holding Group, Inc. "We extend a warm welcome to Dr. Stefan Kasian, who we are confident will build upon our successes and drive KRTL Biotech, Inc. forward into an exciting future."
About KRTL Holding Group, Inc.
We are interested in having a competitive edge in the marketplace, through mergers and acquisitions, collaborations, and strategic alliances with specific partners.
KRTL Holding Group Inc. operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. Each company has its focus on specific industries including bio and Agri-Technology, to international trade and distribution of these technologies and services. This strategy allows KRTL Holding Group to capitalize on investment opportunities, and partnerships, creating value for its shareholders.
Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.